EUVIMEDEUVIMED entdecken
Open Access

Clinical and immunological outcomes of SARS-CoV-2 infection in patients with inborn errors of immunity receiving different brands and doses of COVID-19 vaccines

Esra Karabiber, Özge Atik, Fatma Merve Tepetam, Bilgehan Ergan, Arzu İlki, Elif Karakoç Aydıner, Ahmet Özen, Fatma Özyer, Safa Barış

Tuberk Toraks · 2023

DOI: 10.5578/tt.20239705 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tuberk Toraks, 2023. Verfasst von Esra Karabiber und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Adult Immunology and Allergy, Department of Chest Diseases, Marmara University Pendik Training and Research Hospital, İstanbul, Türkiye. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Vaccines against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) provide successful control of the coronavirus-2019 (COVID-19) pandemic. The safety and immunogenicity studies are encouraging in patients with inborn errors of immunity (IEI); however, data about mortality outcomes and severe disease after vaccination still need to be fully addressed. Therefore, we aimed to determine the clinical and immunological outcomes of SARS-CoV-2 infection in patients with IEI who have received vaccination. Materials and Methods: Eighty-eight patients with a broad range of molecular etiologies were studied; 45 experienced SARS-CoV-2 infection. Infection outcomes were analyzed in terms of genetic etiology, background clinical characteristics, and immunization history, including the type and number of doses received and the time elapsed since vaccination. In addition, anti-SARS-CoV-2 antibodies were quantified using electrochemiluminescent immunoassay.

Results

Patients were immunized using one of the three regimens: inactivated (Sinovac, Coronavac®), mRNA (BNT162b2, Comirnaty®, Pfizer-Biontech), and a combination. All three regimens induced comparable anti-SARS-CoV-2 IgG levels, with no differences in the adverse events. Among 45 patients with COVID-19, 26 received a full course of vaccination, while 19 were vaccine-naive or received incomplete dosing. No patients died due to COVID-19 infection. The fully immunized group had a lower hospitalization rate (23% vs. 31.5%) and a shorter symptomatic phase than the others. Among the fully vaccinated patients, serum IgM and E levels were significantly lower in hospitalized patients than non-hospitalized patients.

Conclusion

COVID-19 vaccines were well-tolerated by the IEI patients, and a full course of immunization was associated with lower hospitalization rates and a shorter duration of COVID-19 symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesHumansBNT162 VaccineSARS-CoV-2VaccinationVaccines, Inactivated

Substanzen

BNT162 VaccineCOVID-19 Vaccinessinovac COVID-19 vaccineVaccines, Inactivated

Autor:innen und Institutionen

  • Division of Adult Immunology and Allergy, Department of Chest Diseases, Marmara University Pendik Training and Research Hospital, İstanbul, Türkiye.
  • Division of Adult Immunology and Allergy, Department of Chest Diseases, Süreyyapaşa Training and Research Hospital, İstanbul, Türkiye.
  • Department of Medical Microbiology, Marmara University Faculty of Medicine, İstanbul, Türkiye.
  • Department of Pediatric Allergy and Immunology, Marmara University Faculty of Medicine, İstanbul, Türkiye.
  • İstanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, İstanbul, Türkiye.
  • Işıl Berat Barlan Center for Translational Medicine, İstanbul, Türkiye.

Zitieren

APA

Karabiber, E., Atik, Ö., Tepetam, F. M., Ergan, B., İlki, A., Karakoç Aydıner, E., Özen, A., Özyer, F., & Barış, S. (2023). Clinical and immunological outcomes of SARS-CoV-2 infection in patients with inborn errors of immunity receiving different brands and doses of COVID-19 vaccines. Tuberk Toraks. https://doi.org/10.5578/tt.20239705

Vancouver

Karabiber E, Atik Ö, Tepetam FM, Ergan B, İlki A, Karakoç Aydıner E, et al. Clinical and immunological outcomes of SARS-CoV-2 infection in patients with inborn errors of immunity receiving different brands and doses of COVID-19 vaccines. Tuberk Toraks. 2023. doi:10.5578/tt.20239705

BibTeX
@article{Karabiber2023,
  author = {Karabiber, Esra and Atik, Özge and Tepetam, Fatma Merve and Ergan, Bilgehan and İlki, Arzu and Karakoç Aydıner, Elif and Özen, Ahmet and Özyer, Fatma and Barış, Safa},
  title = {Clinical and immunological outcomes of SARS-CoV-2 infection in patients with inborn errors of immunity receiving different brands and doses of COVID-19 vaccines},
  journal = {Tuberk Toraks},
  year = {2023},
  doi = {10.5578/tt.20239705}
}
Kostenlos starten →